País: Canadá
Língua: inglês
Origem: Health Canada
HAEMAGGLUTININ-STRAIN A (H3N2); HAEMAGGLUTININ-STRAIN B; HAEMAGGLUTININ-STRAIN A (H1N1)
SANOFI PASTEUR LIMITED
J07BB02
INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN
15MCG; 15MCG; 15MCG
SUSPENSION
HAEMAGGLUTININ-STRAIN A (H3N2) 15MCG; HAEMAGGLUTININ-STRAIN B 15MCG; HAEMAGGLUTININ-STRAIN A (H1N1) 15MCG
INTRAMUSCULAR
0.5ML
Schedule D
VACCINES
Active ingredient group (AIG) number: 0324197003; AHFS:
CANCELLED POST MARKET
2019-07-18
SANOFI PASTEUR SECTION 1.3.1 CLEAN PRODUCT MONOGRAPH 314 AND 329 – VAXIGRIP ® PAGE 1 OF 23 PRODUCT MONOGRAPH VAXIGRIP ® INACTIVATED INFLUENZA VACCINE TRIVALENT TYPES A AND B (SPLIT VIRION ) Suspension for Injection Active Immunizing Agent for the Prevention of Influenza ATC Code: J07BB02 Manufactured by: SANOFI PASTEUR SA _ _ Lyon, France Distributed by: SANOFI PASTEUR LIMITED Toronto, Ontario, Canada DATE OF REVISION: April 2014 CONTROL NO.: 173380 DATE OF APPROVAL: 30 April 2014 SANOFI PASTEUR SECTION 1.3.1 CLEAN PRODUCT MONOGRAPH 314 AND 329 – VAXIGRIP ® PAGE 2 OF 23 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................... 4 SUMMARY PRODUCT INFORMATION ............................................................................. 4 DESCRIPTION ........................................................................................................................... 4 INDICATIONS AND CLINICAL USE .................................................................................... 4 CONTRAINDICATIONS .......................................................................................................... 5 HYPERSENSITIVITY ................................................................................................................... 5 WARNINGS AND PRECAUTIONS ........................................................................................ 5 GENERAL ............................................................................................................................ 5 HEMATOLOGIC ......................................................................................................................... 6 IMMUNE ............................................................................................................................ 6 NEUROLOGIC ............................................................................................................................ 6 RESPIRATORY ........................................................................ Leia o documento completo